T. Rowe Price Associates
ANRO icon

T. Rowe Price Associates’s Alto Neuroscience ANRO Stock Holding History

T. Rowe Price Associates’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.35M Buy
371,208
+340,980
+1,128% +$6.32M ﹤0.01% 1256
2025
Q4 		$539K Sell
30,228
-29,200
-49% -$368K ﹤0.01% 2360
2025
Q3 		$239K Hold
59,428
– – ﹤0.01% 2718
2025
Q2 		$131K Buy
59,428
+5,499
+10% +$13.1K ﹤0.01% 2839
2025
Q1 		$117K Sell
53,929
-790,894
-94% -$2.83M ﹤0.01% 2789
2024
Q4 		$3.58M Buy
844,823
+36,319
+4% +$227K ﹤0.01% 1392
2024
Q3 		$9.25M Buy
808,504
+162,672
+25% +$1.99M ﹤0.01% 1151
2024
Q2 		$6.9M Buy
645,832
+8,228
+1% +$107K ﹤0.01% 1167
2024
Q1 		$9.79M Buy
+637,604
New +$9.98M ﹤0.01% 1114

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

T. Rowe Price Associates's ANRO Position: Q1 2026 in Review

T. Rowe Price Associates increased its Alto Neuroscience (ANRO) stake by 1,128% in Q1 2026, buying an estimated $6.32M and bringing the position to 371,208 shares worth $8.35M. The position accounts for ﹤0.01% of the portfolio, ranked #1256.

T. Rowe Price Associates first reported a position in ANRO in Q1 2024 and has held it in 9 quarters since. The position peaked at $9.79M in Q1 2024. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • T. Rowe Price Associates held 371,208 shares of Alto Neuroscience worth $8.35M as of Q1 2026.
  • T. Rowe Price Associates bought 340,980 Alto Neuroscience shares in Q1 2026, an estimated $6.32M.
  • Alto Neuroscience made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1256 holding.
  • T. Rowe Price Associates first reported a position in Alto Neuroscience in Q1 2024 and has held it in 9 quarters since.
  • T. Rowe Price Associates's Alto Neuroscience position peaked at $9.79M in Q1 2024.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.